COMPANY:

Myriad Genetics

"Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.1-4 This combination helps identify if a patient is safe for active surveillance (AS) and how refinement of AS intensity can be personalized.4-8 This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company. The Prolaris + AI test is the only test where AS metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts.1-4 The Prolaris + AI test will continue to help doctors identify patients who are safe for single-modal treatment."

"Myriad Genetics...today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers."

"Myriad Genetics...today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer."

"Myriad Genetics...will present new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular Residual Disease) Test, Prolaris® Prostate Cancer Prognostic Test and MyRisk® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification, and inherited cancer risk assessment."

''Myriad Genetics, Inc...today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types.''

''Myriad Genetics, Inc...announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium® (SABCS)...The company will share the latest advances in the MyRisk® Hereditary Cancer Test that support guideline-driven treatment decisions. Additionally, the company is presenting data on its Precise® Molecular Residual Disease (MRD) Test.''

''Myriad Genetics, Inc...today announced MyRisk® Hereditary Cancer Test—the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and guidelines from American Society of Clinical Oncology (ASCO).''

"Myriad Genetics...today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disorder (MDD). Further, the post-hoc analysis showed that this benefit persisted over six months with no evidence of changing over time."

"Myriad Genetics...announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment."

"Myriad Genetics, Inc...today announced The Lancet Oncology published a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC)."

"ANGLE plc...is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc...Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay."

"Myriad Genetics...today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad’s ultra-sensitive Precise™ MRD Test to detect and monitor ctDNA in patients."